20/20 Biolabs, Inc.
AIDX
$0.52
-$0.04-6.51%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 730.60K | 353.40K | 538.30K | 418.00K | 535.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 730.60K | 353.40K | 538.30K | 418.00K | 535.10K |
| Cost of Revenue | 425.80K | 290.50K | 407.90K | 272.90K | 371.80K |
| Gross Profit | 304.70K | 62.90K | 130.40K | 145.10K | 163.30K |
| SG&A Expenses | 1.29M | 1.35M | 912.70K | 814.20K | 814.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.97M | 1.80M | 1.45M | 1.22M | 1.38M |
| Operating Income | -1.24M | -1.44M | -912.80K | -800.20K | -845.70K |
| Income Before Tax | -1.51M | -2.17M | -1.31M | -825.50K | -840.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.51M | -2.17M | -1.31M | -825.50K | -840.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.51M | -2.17M | -1.31M | -825.50K | -840.90K |
| EBIT | -1.24M | -1.44M | -912.80K | -800.20K | -845.70K |
| EBITDA | -1.22M | -1.43M | -892.70K | -779.10K | -824.60K |
| EPS Basic | -0.26 | -0.28 | -0.25 | -0.17 | -0.17 |
| Normalized Basic EPS | -0.09 | -0.18 | -0.16 | -0.11 | -0.11 |
| EPS Diluted | -0.26 | -0.28 | -0.25 | -0.17 | -0.17 |
| Normalized Diluted EPS | -0.09 | -0.18 | -0.16 | -0.11 | -0.11 |
| Average Basic Shares Outstanding | 10.79M | 7.66M | 5.17M | 4.90M | 4.82M |
| Average Diluted Shares Outstanding | 10.79M | 7.66M | 5.17M | 4.90M | 4.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |